Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 14/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522718 | 1.00 | JAK2 (0.51) | JAK2JAK1NAMPTPTPN2PTPN1 | |
| SCHEMBL26619952 | 0.85 | FAAH (0.39) | JAK2JAK1NAMPT | |
| SCHEMBL31195181 | 0.85 | FAAH (0.39) | JAK2JAK1NAMPT | |
| SCHEMBL24433504 | 0.84 | MGLL (0.44) | — | |
| SCHEMBL24433506 | 0.84 | MGLL (0.44) | — | |
| SCHEMBL29657032 | 0.84 | MGLL (0.44) | — | |
| SCHEMBL24433420 | 0.84 | MGLL (0.44) | — | |
| SCHEMBL24433501 | 0.83 | NAMPT (0.56) | JAK2JAK1NAMPTPTPN2PTPN1 | |
| SCHEMBL30522720 | 0.83 | NAMPT (0.56) | JAK2JAK1NAMPTPTPN2PTPN1 | |
| SCHEMBL20641873 | 0.83 | NAMPT (0.43) | NAMPTPTPN2PTPN1PTPN6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| EP-4244208-A1 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2023-09-20 | — | — | EP | disclosed |
| CN-116547274-A | MAGL inhibitors | H.隆德贝克有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | JAK2 2686/4885JAK1 2670/4885NAMPT 2121/4885 |
| US-20220153721-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | JAK2 2686/4885JAK1 2670/4885NAMPT 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.